NZ333866A - Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents - Google Patents

Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents

Info

Publication number
NZ333866A
NZ333866A NZ333866A NZ33386697A NZ333866A NZ 333866 A NZ333866 A NZ 333866A NZ 333866 A NZ333866 A NZ 333866A NZ 33386697 A NZ33386697 A NZ 33386697A NZ 333866 A NZ333866 A NZ 333866A
Authority
NZ
New Zealand
Prior art keywords
pressure sensitive
sensitive adhesive
transdermal delivery
salts
adhesive matrix
Prior art date
Application number
NZ333866A
Other languages
English (en)
Inventor
Srinivasan Venkateshwaran
David Fikstad
Charles D Ebert
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of NZ333866A publication Critical patent/NZ333866A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
NZ333866A 1996-09-06 1997-08-29 Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents NZ333866A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/706,624 US5985317A (en) 1996-09-06 1996-09-06 Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
PCT/US1997/015302 WO1998009591A1 (en) 1996-09-06 1997-08-29 Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents

Publications (1)

Publication Number Publication Date
NZ333866A true NZ333866A (en) 2000-08-25

Family

ID=24838399

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333866A NZ333866A (en) 1996-09-06 1997-08-29 Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents

Country Status (11)

Country Link
US (1) US5985317A (enExample)
EP (1) EP0952799A1 (enExample)
JP (1) JP2000517343A (enExample)
KR (1) KR20000068029A (enExample)
AR (1) AR009516A1 (enExample)
AU (1) AU4242797A (enExample)
BR (1) BR9712806A (enExample)
CA (1) CA2262693A1 (enExample)
NZ (1) NZ333866A (enExample)
WO (1) WO1998009591A1 (enExample)
ZA (1) ZA977832B (enExample)

Families Citing this family (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
CA2343100A1 (en) * 1998-09-08 2000-05-04 Srinivasan Venkateshwaran Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6602912B2 (en) 2000-06-30 2003-08-05 Dermatrends, Inc. Transdermal administration of phenylpropanolamine
US6565879B1 (en) 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US6673363B2 (en) * 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
DE10004790B4 (de) * 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
US6642304B1 (en) 2000-02-25 2003-11-04 3M Innovative Properties Company Polyurethane-based adhesives, systems for such adhesives, articles therefrom, and methods of making
US6518359B1 (en) 2000-02-25 2003-02-11 3M Innovative Properties Co. Polyurethane-based pressure-sensitive adhesives, systems for such adhesives, articles therefrom, and methods of making
ES2357699T3 (es) * 2000-04-26 2011-04-28 Watson Pharmaceuticals, Inc. Reducir las experiencias adversas asociada con la terapia de oxibutinina.
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
KR100732948B1 (ko) * 2000-11-22 2007-06-27 아이큐어 주식회사 국소마취용 패취
PT1381352E (pt) * 2001-03-16 2007-07-27 Alza Corp Adesivo transdérmico para administração de fenantil
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
EP1757280A1 (en) 2001-03-16 2007-02-28 ALZA Corporation Transdermal patch for administering sufentanyl
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
CA2463724A1 (en) * 2001-10-16 2003-04-24 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
US20030124178A1 (en) * 2001-12-28 2003-07-03 Haley Jeffrey T. Soft, adherent, soluble oral patch
US20050226915A1 (en) * 2001-12-28 2005-10-13 Oramelts Corporation, A Washington Corporation Method for manufacturing and packaging oral patches with rounded edges
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
AU2003221752A1 (en) * 2002-04-23 2003-11-10 Alza Corporation Transdermal analgesic systems with reduced abuse potential
EP1517684B1 (en) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
EP1530469B1 (en) * 2002-08-20 2009-02-25 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
CL2004000927A1 (es) 2003-04-30 2005-01-28 Purdue Pharma Lp Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal.
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
EP2269606A3 (en) * 2003-10-30 2012-04-25 ALZA Corporation Transdermal analgesic systems having reduced abuse potential
US20050137375A1 (en) * 2003-12-19 2005-06-23 3M Innovative Properties Company Polyurethane-based pressure sensitive adhesives and methods of manufacture
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
JP2007532697A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005118511A2 (en) 2004-05-20 2005-12-15 The Scripps Research Institute Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
EP1786421A2 (en) * 2004-07-09 2007-05-23 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
JP4745747B2 (ja) 2004-08-12 2011-08-10 日東電工株式会社 フェンタニル含有貼付製剤
JP4824963B2 (ja) * 2004-08-12 2011-11-30 日東電工株式会社 貼付材及び貼付製剤
US20070269522A1 (en) * 2004-08-20 2007-11-22 Wold Chad R Transdermal Drug Delivery Device with Translucent Protective Film
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US20060134201A1 (en) * 2004-12-16 2006-06-22 Haley Jeffrey T Collagen troches for treating mouth lesions
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
WO2006134937A1 (ja) * 2005-06-14 2006-12-21 Sekisui Chemical Co., Ltd. 皮膚外用剤
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP1948142B1 (en) * 2005-09-23 2014-04-09 ALZA Corporation High enhancer-loading polyacrylate formulation for transdermal applications
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
JP2009516718A (ja) * 2005-11-23 2009-04-23 ウニベルジテート チューリッヒ 経皮アレルゲン投与によるアレルギー治療
US8349120B2 (en) * 2006-03-07 2013-01-08 Ora Health Corporation Multi-layer patch made on a sheet and enclosed in a blister
WO2007126841A2 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
DE102006019293A1 (de) * 2006-04-21 2007-10-25 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend ein Fentanyl Analogum
US20070248654A1 (en) * 2006-04-21 2007-10-25 Haley Jeffrey T Protective mouth sore discs made with corn starch
US20070248655A1 (en) * 2006-04-21 2007-10-25 Haley Jeffrey T Lenticular shaped protective mouth sore discs
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
EP2292663B1 (en) 2006-08-28 2013-10-02 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
US20080226702A1 (en) * 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
WO2008144320A2 (en) * 2007-05-17 2008-11-27 Endo Pharmaceuticals, Inc. Opioid and methods of making and using the same
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
US20090258061A1 (en) * 2007-10-15 2009-10-15 Johnson & Johnson Once-a-day replacement transdermal administration of fentanyl
AU2008327615B2 (en) * 2007-11-21 2014-08-21 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
WO2009106831A2 (en) * 2008-02-28 2009-09-03 Syntropharma Limited Pharmaceutical composition
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
KR101694931B1 (ko) 2009-01-06 2017-01-10 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
EP2373791B1 (en) 2009-01-06 2016-03-30 Curelon LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
EP2401267B1 (en) * 2009-02-27 2014-01-15 Ambit Biosciences Corporation Jak kinase modulating quinazoline derivatives and their use in methods
WO2010111346A2 (en) * 2009-03-24 2010-09-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Hep-lock and iv site dry mitt
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8871460B2 (en) 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181896A1 (en) 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
CA2796575C (en) 2010-04-13 2018-05-15 Relmada Therapeutics, Inc. Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
HRP20201512T1 (hr) 2010-12-29 2020-12-11 Strategic Science & Technologies, Llc Liječenje erektilne disfunkcije i drugih indikacija
WO2012092523A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
DK3305317T3 (da) 2011-04-21 2020-07-20 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
JP5856153B2 (ja) 2011-05-10 2016-02-09 伊藤忠ケミカルフロンティア株式会社 非水性貼付剤
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
ES3034911T3 (en) 2011-05-10 2025-08-26 Itochu Chemical Frontier Corp Non-aqueous patch
CA2838991A1 (en) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Novel fluoroergoline analogs
SG10201610097WA (en) 2011-08-18 2017-01-27 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
HRP20181230T1 (hr) 2011-09-27 2018-10-05 Itochu Chemical Frontier Corporation Nevodeni flaster
CA2790749A1 (en) * 2011-09-29 2013-03-29 Nitto Denko Corporation Manufacturing method of patch preparation
EP2793580A4 (en) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc NEW DERIVATIVES OF ISO-ERGOLINE
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
SG10201506202RA (en) 2011-12-21 2015-09-29 Map Pharmaceuticals Inc Novel neuromodulatory compounds
HRP20180953T1 (hr) 2012-05-02 2018-07-27 Boehringer Ingelheim International Gmbh Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2861562B1 (en) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
US9364273B2 (en) 2012-08-15 2016-06-14 DePuy Synthes Products, Inc. Drug eluting surgical screw
WO2014068600A1 (en) 2012-11-02 2014-05-08 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising diclofenac
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
CA2895829A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
ES2891755T3 (es) 2013-06-06 2022-01-31 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
WO2014210504A1 (en) * 2013-06-28 2014-12-31 Mitroo Sumair Tape having transdermal analgesic properties
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RS61678B1 (sr) 2014-05-28 2021-05-31 Agenus Inc Anti-gitr antitela i postupci za njihovu primenu
US10071090B2 (en) 2014-07-18 2018-09-11 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
BR112017012344B1 (pt) 2014-12-11 2024-02-06 Pierre Fabre Medicament Anticorpo anti-c10orf54 ou fragmento de ligação ao antígeno do mesmo, conjugado anticorpo-fármaco, composição farmacêutica, kit, seus usos, polinucleotídeo, vetor de expressão e métodos de produção do anticorpo ou fragmento de ligação ao antígeno e de detecção c10orf54 em uma amostra
WO2016099198A1 (ko) * 2014-12-18 2016-06-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 경피흡수제제
ES2862701T3 (es) 2014-12-22 2021-10-07 Univ Rockefeller Anticuerpos agonistas anti-MERTK y usos de los mismos
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
EP3247357A4 (en) 2015-01-20 2018-07-11 Xoc Pharmaceuticals, Inc Isoergoline compounds and uses thereof
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
HUE061070T2 (hu) 2015-03-03 2023-05-28 Kymab Ltd Ellenanyagok, alkalmazások és eljárások
US20180156807A1 (en) 2015-04-29 2018-06-07 New York University Method for treating high-grade gliomas
EP3303394B1 (en) 2015-05-29 2020-04-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
CN108883103A (zh) 2015-12-02 2018-11-23 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
EP3426352A4 (en) 2016-03-08 2019-11-13 Los Gatos Pharmaceuticals, Inc. CAMPTOTHECIN DERIVATIVES AND USES THEREOF
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
DK3454904T3 (da) 2016-05-13 2023-02-06 Pasteur Institut Inhibering af beta-2-nikotiniske acetylcholinreceptorer til at behandle patologi ved Alzheimers sygdom
KR102366813B1 (ko) 2016-05-27 2022-02-24 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
NZ792355A (en) 2016-10-11 2025-12-19 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR102539159B1 (ko) 2016-11-07 2023-06-02 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
SG10201912560YA (en) 2016-12-07 2020-02-27 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
JP7307681B2 (ja) 2017-02-17 2023-07-12 カムリス インターナショナル インコーポレイテッド 汎用性抗毒素
MX2021015220A (es) 2017-02-17 2022-12-01 Eidos Therapeutics Inc Procesos para preparar ácido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
EP3609528A4 (en) 2017-04-10 2020-12-23 Curemark, LLC COMPOSITIONS FOR THE TREATMENT OF ADDICTION
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
DK3618863T3 (da) 2017-05-01 2023-08-21 Agenus Inc Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
BR112019025420A2 (pt) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. Compostos policíclicos e usos destes
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
KR102574549B1 (ko) 2017-06-27 2023-09-07 주식회사 뉴라클사이언스 항-fam19a5 항체 및 이의 용도
KR102472683B1 (ko) 2017-06-27 2022-12-01 주식회사 뉴라클사이언스 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
JP7034499B2 (ja) 2017-06-27 2022-03-14 ニューラクル サイエンス カンパニー リミテッド 線維症の治療のための抗ｆａｍ１９ａ５抗体の用途
JP7012384B2 (ja) 2017-06-27 2022-02-14 ニューラクル サイエンス カンパニー リミテッド 癌治療のための抗ｆａｍ１９ａ５抗体の用途
US11571401B2 (en) 2017-09-01 2023-02-07 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
WO2019069229A1 (en) 2017-10-02 2019-04-11 Neuracle Science Co., Ltd. USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
US20190175519A1 (en) * 2017-12-08 2019-06-13 Teikoku Pharma Usa, Inc. Naloxone Transdermal Delivery Devices and Methods for Using the Same
CA3094711A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
JP7171081B2 (ja) 2018-04-24 2022-11-15 ニューラクル サイエンス カンパニー リミテッド 神経病性疼痛の治療のための配列類似性１９、メンバーａ５抗体を有する抗ファミリーの用途
EP3790898A4 (en) 2018-05-10 2022-03-02 Neuracle Science Co., Ltd SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
WO2020008370A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
WO2020037189A1 (en) 2018-08-17 2020-02-20 Eidos Therapeutics, Inc. Formulations of ag10
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
EP3867272A4 (en) 2018-10-16 2022-08-03 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES
KR20210093950A (ko) 2018-11-16 2021-07-28 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 면역 관문 저해제의 조합으로 종양을 치료하는 방법
WO2020118042A1 (en) 2018-12-05 2020-06-11 Jacobs Wagner Christine Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
JP7239216B2 (ja) 2018-12-27 2023-03-14 ニューラクル サイエンス カンパニー リミテッド 粥状硬化症を治療するための抗ｆａｍ１９ａ５抗体の使用
EP3906260A4 (en) 2019-01-02 2022-08-31 Neuracle Science Co., Ltd SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5 AND METHOD OF USE THEREOF
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
EP4636054A3 (en) 2019-05-20 2025-12-31 NIRvana Sciences Inc. Narrow-emitting dyes, compositions comprising them, and processes for their manufacture and use
CN114222803B (zh) 2019-05-20 2025-01-07 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
CA3154608A1 (en) 2019-09-16 2021-03-25 Dice Alpha, Inc. Il-17a modulators and uses thereof
CN114945409A (zh) 2020-01-13 2022-08-26 新免疫技术有限公司 用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法
WO2021158783A1 (en) 2020-02-05 2021-08-12 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US12364692B2 (en) 2020-02-14 2025-07-22 Teikoku Pharma Usa, Inc. Topical naloxone compositions and methods for using the same
KR20220161416A (ko) * 2020-03-30 2022-12-06 신케이 테라퓨틱스, 아이엔씨. 덱스트로메토르판의 경피 전달
GB2593902B (en) 2020-04-07 2022-04-13 Actimed Therapeutics Ltd Salt of a pharmaceutical compound
EP4149471A4 (en) 2020-06-30 2024-07-10 Prosetta Biosciences, Inc. ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4232070A1 (en) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Methods of inducing stem cell mobilization
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
EP4240408A1 (en) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
WO2023069770A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
IL312506A (en) 2021-11-08 2024-07-01 Progentos Therapeutics Inc Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
EP4456907A1 (en) 2021-12-30 2024-11-06 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
EP4433040A4 (en) 2022-01-03 2025-11-12 Lilac Therapeutics Inc ACYCLIC THIOL PRODRUGS
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023168329A2 (en) 2022-03-02 2023-09-07 Mitopower, Inc. Novel prodrugs derived from nicotinic acid and ribose
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2024086852A1 (en) 2022-10-21 2024-04-25 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
EP4615485A1 (en) 2022-11-07 2025-09-17 NeoImmuneTech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024211807A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
WO2024211796A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
AU2024269869A1 (en) 2023-05-09 2025-10-16 Progentos Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2024243048A1 (en) 2023-05-19 2024-11-28 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
US20250179197A1 (en) 2023-10-23 2025-06-05 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4262003A (en) * 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
US5310559A (en) * 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4564010A (en) * 1984-04-18 1986-01-14 Daubert Coated Products Inc. Pressure sensitive adhesive film for medical use
EP0190262B1 (en) * 1984-07-24 1990-12-27 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4904475A (en) * 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5002773A (en) * 1989-09-29 1991-03-26 Marion Merrell Dow Inc. Transdermal delivery of (+) (2S,3S)-3-acetoxy-8-chloro-5-(2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4-(5H)-one
US5230896A (en) * 1989-10-12 1993-07-27 Warner-Lambert Company Transdermal nicotine delivery system
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
JP2849950B2 (ja) * 1990-11-30 1999-01-27 日東電工株式会社 経皮吸収製剤
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug

Also Published As

Publication number Publication date
CA2262693A1 (en) 1998-03-12
WO1998009591A1 (en) 1998-03-12
US5985317A (en) 1999-11-16
AU4242797A (en) 1998-03-26
AR009516A1 (es) 2000-04-26
JP2000517343A (ja) 2000-12-26
KR20000068029A (ko) 2000-11-25
EP0952799A1 (en) 1999-11-03
ZA977832B (en) 1998-03-19
BR9712806A (pt) 1999-11-23

Similar Documents

Publication Publication Date Title
NZ333866A (en) Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US20110178044A1 (en) Transdermal administration of hydrophilic drugs using permeation enhancer composition
CA2304784A1 (en) A transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, and the manufacturing method thereof
FI103478B (fi) Menetelmä transdermaalisen terapeuttisen järjestelmän valmistamiseksi, jossa vaikuttavan aineen virtausta on suurennettu
EP0481939B1 (en) Twin patch applicator
CA2145631A1 (en) Two-phase matrix for sustained release drug delivery device
CA2020557A1 (en) Topically administrable pharmaceutical preparations
US20080138390A1 (en) Transdermal Delivery System For Use With Basic Permeation Enhancers
NO972565L (no) Estradiolholdig plaster
NO953792D0 (no) Plaster med virksomme stoffer for avgivelse av östradiol til huden
FI951887A0 (fi) Laastarit haihtuvien, farmaseuttisesti vaikuttavien, kemiallisesti emäksisten aineiden antamiseen ihon läpi, ja menetelmä niiden valmistamiseksi
CA2387143A1 (en) Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
US5139786A (en) Topical formulations
FI953532A0 (fi) Nitroglyserolia sisältävä laastari, menetelmä sen valmistamiseksi ja sen käyttö
AU638034B2 (en) Topical formulations
US5972376A (en) Transdermal system of tacrine/selegilin-plaster
NZ234919A (en) Polymeric matrix or reservoir transdermal nitroglycerin patch which contains n-methyl-2-pyrrolidone and/or penetration enhancer(s); preparatory processes
KR100212972B1 (ko) 인도메타신의 경피흡수제제
TWI298253B (en) Transdermal delivery of lasofoxifene
HK1132922A (en) Transdermal therapeutic system comprising ion pair micro-reservoirs